Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7999552 | 0.90 | PPARD (0.60) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL17961069 | 0.88 | PPARD (0.55) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL73826 | 0.88 | CYP1A2 (0.52) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL16731022 | 0.86 | KDM4E (0.59) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL11378720 | 0.86 | PPARD (0.54) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL5661565 | 0.86 | MAPT (0.49) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL7293667 | 0.86 | MAPT (0.49) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL73790 | 0.86 | PPARD (0.54) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL27516005 | 0.86 | PPARD (0.54) | PPARDMAPTL3MBTL1NPSR1LTB4R | |
| SCHEMBL3053018 | 0.86 | TAAR1 (0.61) | PPARDMAPTL3MBTL1NPSR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452372-A | It is functionalized phenylene ether oligomer, the curable compositions comprising it and thermoset composition and its product and preparation method | SABIC GLOBAL TECHNOLOGIES BV | 2019-11-15 | — | — | CN | disclosed |
| CN-110408019-A | Phenylene ether oligomer, the curable compositions comprising phenylene ether oligomer and thermoset composition as derived from it | SABIC GLOBAL TECHNOLOGIES BV | 2019-11-05 | — | — | CN | disclosed |
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| CN-106660953-A | High heat monomers and methods of use thereof | 沙特基础工业全球技术有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9493505-B2 | Macrocyclic modulators of the ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | OCERA THERAPEUTICS LLC | 2016-08-04 | — | — | US | disclosed |
| CN-105473550-A | Ido inhibitors | BRISTOL MYERS SQUIBB CO | 2016-04-06 | — | — | CN | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| EP-1854798-A2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Bristol-Myers Squibb Company (US) | 2007-11-14 | — | — | EP | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | PPARD 1156/4885MAPT 2759/4885L3MBTL1 1727/4885 |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | PPARD 234/4885MAPT 4693/4885L3MBTL1 1687/4885 |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | PPARD 1145/4885MAPT 3219/4885L3MBTL1 2098/4885 |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | PPARD 234/4885MAPT 4693/4885L3MBTL1 1687/4885 |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | PPARD 271/4885MAPT 4785/4885L3MBTL1 1850/4885 |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | PPARD 1156/4885MAPT 2759/4885L3MBTL1 1727/4885 |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | PPARD 234/4885MAPT 4693/4885L3MBTL1 1687/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | PPARD 271/4885MAPT 4785/4885L3MBTL1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.